Literature DB >> 31551259

Natalizumab wearing-off symptoms: Patients with MS on extended interval dosing may not "mind the gap".

Ellen M Mowry1, Dennis Bourdette2.   

Abstract

Entities:  

Year:  2019        PMID： 31551259     DOI： 10.1212/WNL.0000000000008358

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  2 in total

Review 1.  Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis.

Authors:  H P Hartung; C Warnke; F Schweitzer; S Laurent; G R Fink; Michael H Barnett
Journal:  J Neurol       Date:  2020-02-08       Impact factor: 4.849

2.  Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic.

Authors:  Giuseppe Magro; Stefania Barone; Federico Tosto; Antonio De Martino; Domenico Santange Lo; Lucia Manzo; Angelo Pascarella; Pietro Bruno; Marilisa Pasquale; Antonio Gambardella; Paola Valentino
Journal:  J Neurol       Date:  2022-10-13       Impact factor: 6.682
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.